Market Overview

UPDATE: Taglich Brothers Raises PT to $13.25 on Novadaq Technologies on Valuation

Share:
Related
Morning Market Movers
Profound Medical Appoints Dr. Arun Menawat To Board Of Directors
Novadaq Technologies' (NVDQ) CEO Arun Menawat on Q2 2015 Results - Earnings Call Transcript (Seeking Alpha)

Taglich Brothers reiterated its Buy rating on Novadaq Technologies (NASDAQ: NVDQ) and increased its price target from $11 to $13.25.

Taglich Brothers commented, "Reconstructive, cardiac and urological surgery markets have been penetrated to an extent that has made Novadaq cash flow positive. Novadaq aims to commercialize, on its own, the PINPOINT endoscopic imaging systems for minimally invasive surgeries. Substantial development costs for PINPOINT will continue to burn cash through next year. But fortified with $37 million in proceeds from a common stock offering, Novadaq is well prepared for expanded product development and penetration of additional large markets."

Taglich Brothers closed at $9.11 on Wednesday.

Latest Ratings for NVDQ

DateFirmActionFromTo
Jun 2015BTIG ResearchInitiates Coverage onNeutral
Apr 2015Canaccord GenuityMaintainsBuy
Apr 2015Stifel NicolausMaintainsBuy

View More Analyst Ratings for NVDQ
View the Latest Analyst Ratings

Posted-In: taglich brothersAnalyst Color Price Target Pre-Market Outlook Analyst Ratings

 

Related Articles (NVDQ)

Get Benzinga's Newsletters